https://www.selleckchem.com/products/og-l002.html
San Diego, CA, May 2019. Supported by Takeda Pharmaceuticals. Breast cancer is recognized as the most common cause of malignancy and cancer death worldwide; however, mutations in the cancer-related BRCA genes are detected in only 2-3% of patients with breast cancer. Because next-generation sequencing technology allows concurrent sequencing of numerous target genes, diverse cancer-susceptibility genes are now being evaluated, although their significance in clinical practice remains unclear. In this study, we developed a sequencing panel
Like
Comment
Share
